Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Electrical nerve stimulation helps mitigate movement-evoked pain in fibromyalgia

12 Jan 2020

Use of active transcutaneous electrical nerve stimulation (TENS) in fibromyalgia (FM) patients receiving treatment results in a favourable reduction in movement-evoked pain, according to the results of a trial.

The trial randomized female FM patients receiving steady medication to active TENS (n=103), placebo TENS (n=99) or no TENS (n=99). TENS was applied to the lumbar and cervicothoracic regions using a modulated frequency (2–125Hz) at the highest tolerable intensity, with patients instructed to use it at home 2h/day during activity for 4 weeks.

Movement‐evoked pain (primary outcome) and fatigue were rated on an 11‐point scale before and during application of TENS.

After 4 weeks, movement-evoked pain decreased significantly with active TENS vs placebo TENS (mean difference, –1.0, 95 percent confidence interval [CI], –1.8 to –0.2; p=0.008) and no TENS (mean difference, –1.8, 95 percent CI, –2.6 to –1.0; p<0.0001). The same was observed for fatigue (mean difference, –1.4, 95 percent CI, –2.4 to –0.4; p=0.001 and mean difference, –1.9, 95 percent CI, –2.9 to –0.9; p=0.0001, respectively).

Significantly more patients in the active‐TENS group reported improvement in the global impression of change than in the placebo‐TENS and no-TENS groups (70 percent vs 31 percent and 9 percent, respectively; p-both<0.0001).

There were no reports of TENS‐related serious adverse events, with <5 percent of the overall population experiencing minor adverse events with TENS.

Additional investigation is warranted to examine effectiveness in a real world, pragmatic setting to establish clinical importance of the present data, according to researchers.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).